Navigation Links
ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
Date:5/19/2010

LOS ANGELES, May 19 /PRNewswire/ -- ImaginAb, Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group of Companies) have concluded two research collaboration agreements around a clinical therapeutic antibody asset currently under development by GSK in the field of oncology.

"ImaginAb is pleased to have formalized this collaboration with the GSK CIC," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Not only does GSK have an excellent biologics pipeline, but the company's large-scale commitment to diagnostic imaging is extremely impressive and this particular collaboration is a natural fit with ImaginAb's technology platform."

"Our collaboration with ImaginAb for antibody fragment imaging is part of our further exploration of the role of biologics in diagnostic imaging with Positron Emission Tomography (PET), an increasingly important clinical modality and a tool that is of significant interest to pharma in the discovery and development of new therapeutics," commented Dr. Paul Matthews, VP for Translational Research and Head of the GSK CIC. "As we expand and develop our pipeline, technologies such as ImaginAb's recombinant antibody fragment engineering technology may help us to look at targeted molecular therapeutics in new ways."

About GSK Clinical Imaging Centre

GlaxoSmithKline (GSK), Imperial College London (ICL) and the Medical Research Centre (MRC) have established a unique research collaboration in medical imaging, creating a Clinical Imaging Centre (CIC) based at Hammersmith Hospital in West London. The GSK CIC uses and advances the latest technologies in magnetic resonance imaging (MRI) and positron emission tomography (PET). Research focuses on cancer, stroke, neurological and psychiatric diseases.

GSK is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

About ImaginAb

Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is an early-stage biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy. The company has a significant pipeline of clinical imaging agents under development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET and microSPECT systems and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
2. North Carolina GlaxoSmithKline Foundation Working With Nonprofits to Promote Health, Science and Education Through Ribbon of Hope Grants
3. Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
4. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
5. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
6. GlaxoSmithKline 14th Annual IMPACT Awards Seek Greater Philadelphia and Camden Healthcare Nonprofits
7. GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
8. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
9. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
10. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
11. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
Breaking Medicine News(10 mins):